Publication of Peer Reviewed Article

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the joint online publication in collaboration with Ankyra Therapeutics entitled 'A pharmacokinetic and pharmacodynamic model of an interleukin-12 (IL-12) anchored-drug conjugate for the treatment of solid tumors' in the Journal of Molecular Cancer Therapeutics, American Association for Cancer Research (AACR).

The full article can be accessed via the following link:

In the publication, a mathematical modelling-based approach to drug development is described, where Physiomics supported Ankyra Therapeutics in determining the mechanism of action and dosing/scheduling of their ANK-101 asset. These results provided valuable insights that guided the translation of the drug into the clinic, and the design of the phase 1 clinical trial.

Dr Peter Sargent, CEO, commented:

"We are pleased to announce yet another publication, written in partnership with one of our long-standing clients, Ankyra Therapeutics. This is our third publication within three months, not only reflecting the impact of our expertise and services on supporting successful drug development programmes, but also the variety of clients we work with.

"These publications reflect the growing utility and impact of mathematical modelling on drug development. With the increasing pressure from regulatory agencies around the world for drug developers to utilise such techniques, these publications evidence how well Physiomics is positioned to support its clients in this growing market".

About Ankyra Therapeutics

Ankyra Therapeutics, a Massachusetts US headquartered business, specialises in the development of novel immunotherapies for the treatment of cancer. The business is developing anchored-drug conjugates to trigger long lasting anti-tumour responses without compromising safety. One such candidate in development by Ankyra Therapeutic is their Cytokine Class IL-12 (ANK-101) asset which has successfully entered the clinic.

About Immunotherapy

Immunotherapy has revolutionised cancer treatment by harnessing the body's immune system to recognise and attack cancer cells more effectively. Unlike traditional treatments such as chemotherapy and radiation, which target both healthy and cancerous cells, immunotherapies provide a more precise and potentially less toxic approach. With breakthroughs in immune checkpoint inhibitors, CAR-T cell therapy and cancer vaccines, immunotherapy has improved survival rates and outcomes for patients with various cancers.